OncoMatch/Clinical Trials/NCT06226129
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Is NCT06226129 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Gadopiclenol for prostate cancer.
Treatment: Gadopiclenol — The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Prior therapy
Cannot have received: surgery
Have already begun therapeutic treatment for prostate cancer including surgery (TURP, prostatectomy)
Cannot have received: radiotherapy
Have already begun therapeutic treatment for prostate cancer including ... radiotherapy
Cannot have received: hormone therapy
Have already begun therapeutic treatment for prostate cancer including ... hormone therapy
Cannot have received: chemotherapy
Have already begun therapeutic treatment for prostate cancer including ... chemotherapy
Lab requirements
Kidney function
Patients with end stage renal failure who are on dialysis, chronic kidney disease, or acute kidney injury are excluded per FDA and ACR guidelines
Patients with end stage renal failure who are on dialysis. Patients who have chronic kidney disease or acute kidney injury are contraindicated for MRI per FDA and ACR (American College of Radiologists) guidelines and would thus be excluded as well.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Columbia University Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06226129 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages